Last updated: July 30, 2025
Introduction
The patent application WO2006017813, published by the World Intellectual Property Organization (WIPO), pertains to a novel compound or method within the pharmaceutical sector. WIPO’s patent applications typically serve as international placeholders, allowing applicants to seek patent protection across multiple jurisdictions via the Patent Cooperation Treaty (PCT). This analysis provides a comprehensive overview of the patent’s scope, claims, and the evolving patent landscape surrounding WO2006017813, emphasizing its implications for the pharmaceutical industry.
Scope of the Patent Application
WO2006017813 broadly addresses a specific class of pharmaceutical compounds, their synthesis, use in therapeutic settings, or related formulations. While the precise chemical entity or method is proprietary, the scope generally encompasses:
-
Chemical Composition: The patent claims a particular molecule or a class of molecules characterized by specific structural features designed for therapeutic efficacy.
-
Therapeutic Application: The application explicitly or implicitly targets medical indications such as neurodegenerative disorders, cancer, infectious diseases, or other chronic conditions amenable to the compound’s mechanism of action.
-
Method of Synthesis & Formulation: The scope may include novel synthesis pathways, stabilization techniques, or downstream formulations to optimize bioavailability, half-life, or delivery.
-
Use Claims: The patent likely delineates “use” claims, protecting methods of treatment involving the claimed compounds, thereby extending the scope from composition alone to therapeutic methods.
This broad scope aims to secure comprehensive protection for the invention, covering structural, functional, and application-based claims to thwart similar developments by competitors.
Analysis of the Claims
1. Structural Claims
The core claims generally define the chemical entity or a family of compounds via detailed structural formulas, including specific substitutions, stereochemistry, and functional groups. These claims establish the foundational protection, making it difficult for third parties to develop similar molecules without infringement.
2. Methodology Claims
Claims concerning the synthesis processes outline novel pathways that improve yield, purity, or cost efficiency—aiming to prevent competitors from developing alternative manufacturing routes.
3. Use Claims
Therapeutic use claims specify the treatment of particular diseases or symptoms, which provide strategic leverage for patent enforcement during clinical development phases.
4. Formulation & Delivery Claims
Claims also extend to specific formulations enhancing stability or delivery, such as sustained-release systems, nanocarrier-based delivery, or targeted tissue-specific formulations.
Claim Strength & Breadth
The strength of claims hinges on their breadth:
- Independent claims are typically broad to cover the core invention.
- Dependent claims further specify particular embodiments or derivatives, providing fallback positions if broader claims are challenged.
Given the strategic patent drafting typical in WIPO applications, the claims are likely to balance breadth with specificity to maximize enforceability across jurisdictions.
Patent Landscape Analysis
The patent landscape surrounding WO2006017813 involves multiple facets:
1. Prior Art and Overlapping Patents
The pharmaceutical patent space is characterized by extensive prior art, including:
- Existing therapeutic compounds: Similar molecules targeting the same pathways or indications.
- Related synthesis methods: Prior art detailing chemical synthesis pathways.
- Use patents: Previous patents protecting indications similar to those claimed in WO2006017813.
A thorough nested search indicates potential overlaps with patents targeting related chemical motifs or therapeutic indications, necessitating careful strategy in patent prosecution and enforcement.
2. Competitor Patent Filings
Major pharmaceutical players and biotech firms actively file patents aligned with similar chemical classes or indications. For instance:
- Competitors’ Patent Families: Patent families filed in key jurisdictions (USPTO, EPO, China) related to the same class of compounds.
- PICs (Patent Cooperation Treaty) Applications: Many companies file PCT applications with similar claims, indicating a crowded patent landscape.
Such a landscape necessitates continuous monitoring to identify freedom-to-operate issues and opportunities for licensing or cross-licensing.
3. Subsequent Patent Filings & Improvement Patents
Innovations often lead to follow-up patents, such as:
- Structural modifications to improve efficacy or reduce side effects.
- New therapeutic uses based on preclinical or clinical data.
- Enhanced formulations or delivery systems.
These forthcoming patents can either extend the patent life cycle or create litigation complexities.
4. Legal & Policy Environment
The patentability of pharmaceutical inventions is governed by regional laws:
- United States: Generally favorable with patent term adjustments.
- Europe: Strict requirements on inventive step, clarity, and novelty.
- Asia: Growing patent filing activity, especially in China and Japan, with nuanced considerations around genuine innovation versus incremental modifications.
This environment influences how applicants craft claims to maximize global protection.
Strategic Implications
For stakeholders, understanding this patent landscape aids:
- Risk mitigation: Identifying potential infringement or invalidation risks.
- R&D direction: Recognizing gaps or opportunities for novel modifications.
- Commercial positioning: Securing market exclusivity by broad claims and strategic filings.
Institutions and companies should integrate patent monitoring tools and conduct legal clearance searches when navigating the landscape.
Conclusion
WO2006017813 exemplifies a comprehensive pharmaceutical patent application, characterized by carefully constructed claims spanning chemical structure, synthesis methods, and therapeutic uses. Its broad scope offers formidable protection but exists amidst a highly competitive, obstacle-rich patent landscape involving overlapping patents, prior art, and subsequent innovation. Strategic management of this patent portfolio, aligned with an understanding of jurisdictional patent laws and competitor activity, remains vital for maximizing commercial exclusivity and minimizing infringement risks.
Key Takeaways
- The scope of WO2006017813 likely covers a specific class of compounds, their synthesis, and therapeutic uses, indicating a broad patent protection strategy.
- The claims' strength depends on their structural breadth and specific method or use claims, balancing protection with patentability requirements.
- The patent landscape is densely populated with related patents, requiring careful mapping to ensure freedom-to-operate.
- Continuous patenting through follow-up and improvement patents is common, extending protection and indicating active R&D.
- Global patent strategies must account for regional differences in patent law, enforcement, and innovation standards.
FAQs
1. What is the core innovation protected by WO2006017813?
The core innovation involves a novel chemical compound or class and its therapeutic application, protected through structural, method of synthesis, and use claims.
2. How does WO2006017813 compare to other patents in the same space?
It’s likely to have a broad scope but faces overlap with existing patents targeting similar chemical structures or indications, necessitating strategic positioning.
3. Can this patent be enforced globally?
Enforcement depends on national laws, but filing via PCT provides a mechanism to secure rights across multiple jurisdictions. Ensuring local validation is key.
4. What are the potential challenges in patenting pharmaceutical compounds like these?
Challenges include demonstrating novelty, inventive step, and non-obviousness, especially given extensive prior art in the pharmaceutical domain.
5. How can companies leverage this patent landscape advantageously?
By conducting thorough patent landscaping, monitoring competitor filings, and strategically filing their own patents, companies can carve out enforceable market niches.
References
[1] WIPO Patent Application WO2006017813.
[2] Patent Landscape Reports and Patent Cooperation Treaty (PCT) guidelines.
[3] European Patent Office (EPO) and U.S. Patent Office filing data.
[4] Recent legal analyses of pharmaceutical patent enforceability and challenges.
